149 related articles for article (PubMed ID: 9919951)
1. Estimation of impurity profiles of drugs and related materials: part 19: theme with variations. Identification of impurities in 3-oxosteroids.
Görög S; Babják M; Balogh G; Brlik J; Dravecz F; Gazdag M; Horváth P; Laukó A; Varga K
J Pharm Biomed Anal; 1998 Dec; 18(4-5):511-25. PubMed ID: 9919951
[TBL] [Abstract][Full Text] [Related]
2. Estimation of impurity profiles of drugs and related materials. Part 14: the role of HPLC/diode-array UV spectroscopy in the identification of minor components (impurities, degradation products, metabolites) in various matrices.
Görög S; Bihari M; Csizér E; Dravetz F; Gazdag M; Herényi B
J Pharm Biomed Anal; 1995 Dec; 14(1-2):85-92. PubMed ID: 8833970
[TBL] [Abstract][Full Text] [Related]
3. Estimation of impurity profiles of drugs and related materials: part XXI. HPLC/UV/MS study of the impurity profile of ethynodiol diacetate.
Babják M; Balogh G; Gazdag M; Görög S
J Pharm Biomed Anal; 2002 Aug; 29(6):1153-7. PubMed ID: 12110402
[TBL] [Abstract][Full Text] [Related]
4. Estimation of impurity profiles of drugs and related materials Part 18. Impurities and degradation products of mazipredone.
Gazdag M; Babják M; Brlik J; Mahó S; Tuba Z; Görög S
J Pharm Biomed Anal; 1998 Sep; 17(6-7):1029-36. PubMed ID: 9884192
[TBL] [Abstract][Full Text] [Related]
5. Estimation of impurity profiles in drugs and related materials. Part 11--The role of chromatographic and spectroscopic methods in the estimation of side-reactions in drug syntheses.
Görög S; Balogh G; Csehi A; Csizér E; Gazdag M; Halmos Z; Hegedüs B; Herényi B; Horváth P; Laukó A
J Pharm Biomed Anal; 1993; 11(11-12):1219-26. PubMed ID: 8123737
[TBL] [Abstract][Full Text] [Related]
6. Analysis of steroids. XXXVIII. The use of high-performance liquid chromatography with diode-array UV detection for estimating impurity profiles of steroid drugs.
Görög S; Herényi B
J Chromatogr; 1987 Jul; 400():177-86. PubMed ID: 3667745
[TBL] [Abstract][Full Text] [Related]
7. Drug impurity profiling strategies.
Görög S; Babják M; Balogh G; Brlik J; Csehi A; Dravecz F; Gasdag M; Horváth P; Laukó A; Varga K
Talanta; 1997 Sep; 44(9):1517-26. PubMed ID: 18966892
[TBL] [Abstract][Full Text] [Related]
8. Forced degradation and impurity profiling: recent trends in analytical perspectives.
Jain D; Basniwal PK
J Pharm Biomed Anal; 2013 Dec; 86():11-35. PubMed ID: 23969330
[TBL] [Abstract][Full Text] [Related]
9. Impurity Profile of Bronchodilators used in Asthma: A Critical Review.
Prajapati KJ; Kothari CS
Curr Drug Discov Technol; 2018; 15(4):272-304. PubMed ID: 28875855
[TBL] [Abstract][Full Text] [Related]
10. [Estimation of impurity profiles of drugs and related materials. 20. Methodological problems in the identification and determination of organic impurities].
Görög S
Acta Pharm Hung; 2000; 70(3-6):131-7. PubMed ID: 11379019
[TBL] [Abstract][Full Text] [Related]
11. Estimation of impurity profiles of drugs and related materials. 12. Isolation and identification of an isomeric impurity in danazol.
Balogh G; Csizér E; Ferenczy GG; Halmos Z; Herényi B; Horváth P; Laukó A; Görög S
Pharm Res; 1995 Feb; 12(2):295-8. PubMed ID: 7784348
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and Physicochemical Characterization of the Process-Related Impurities of Eplerenone, an Antihypertensive Drug.
Dams I; Białońska A; Cmoch P; Krupa M; Pietraszek A; Ostaszewska A; Chodyński M
Molecules; 2017 Aug; 22(8):. PubMed ID: 28809817
[TBL] [Abstract][Full Text] [Related]
13. Screening of synthetic PDE-5 inhibitors and their analogues as adulterants: analytical techniques and challenges.
Patel DN; Li L; Kee CL; Ge X; Low MY; Koh HL
J Pharm Biomed Anal; 2014 Jan; 87():176-90. PubMed ID: 23721687
[TBL] [Abstract][Full Text] [Related]
14. NMR and mass spectrometric characterization of vinblastine, vincristine and some new related impurities--part II.
Háda V; Dubrovay Z; Lakó-Futó A; Galambos J; Gulyás Z; Aranyi A; Szántay C
J Pharm Biomed Anal; 2013 Oct; 84():309-22. PubMed ID: 23177164
[TBL] [Abstract][Full Text] [Related]
15. Characterization and quantitative determination of impurities in piperaquine phosphate by HPLC and LC/MS/MS.
Dongre VG; Karmuse PP; Ghugare PD; Gupta M; Nerurkar B; Shaha C; Kumar A
J Pharm Biomed Anal; 2007 Jan; 43(1):186-95. PubMed ID: 16916594
[TBL] [Abstract][Full Text] [Related]
16. Development of Impurity Profiling Methods Using Modern Analytical Techniques.
Ramachandra B
Crit Rev Anal Chem; 2017 Jan; 47(1):24-36. PubMed ID: 27070830
[TBL] [Abstract][Full Text] [Related]
17. Estimation of impurity profiles of drugs and related materials Part 15. Identification of minor impurities in cimetidine.
Halmos Z; Szántay C; Brlik J; Csehi A; Varga K; Horváth P; Kislaki M; Domány G; Nemes A; Görög S
J Pharm Biomed Anal; 1996 Oct; 15(1):1-5. PubMed ID: 8895070
[TBL] [Abstract][Full Text] [Related]
18. Isolation and identification of three potential impurities of pholcodine bulk drug substance.
Denk OM; Gray AI; Skellern GG; Watson DG
J Pharm Pharmacol; 2000 Jul; 52(7):819-29. PubMed ID: 10933132
[TBL] [Abstract][Full Text] [Related]
19. Highly efficient, selective, sensitive and stability indicating RP-HPLC-UV method for the quantitative determination of potential impurities and characterization of four novel impurities in eslicarbazepine acetate active pharmaceutical ingredient by LC/ESI-IT/MS/MS.
Thomas S; Bharti A; Maddhesia PK; Shandilya S; Agarwal A; Dharamvir ; Biswas S; Bhansal V; Gupta AK; Tewari PK; Mathela CS
J Pharm Biomed Anal; 2012 Mar; 61():165-75. PubMed ID: 22178334
[TBL] [Abstract][Full Text] [Related]
20. Screening for impurities in butoprozine.
Drenth BF; Jagersma T; Wormeester AJ; de Zeeuw RA
Pharm Weekbl Sci; 1983 Aug; 5(4):149-52. PubMed ID: 6622208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
